On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...
Shares of biotech company Vertex Pharmaceuticals (VRTX) are down in today’s trading despite the company upping its revenue forecast for the year. Thanks to the growth of its cystic fibrosis (CF) ...
Vertex Pharmaceuticals (NASDAQ:VRTX) presented its fourth quarter and full year 2025 financial results on February 12, 2026, highlighting continued revenue growth and significant pipeline advancements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results